Logo image of SOPH

SOPHIA GENETICS SA (SOPH) Stock Fundamental Analysis

NASDAQ:SOPH - Nasdaq - CH1125843347 - Common Stock - Currency: USD

3.49  -0.26 (-6.93%)

Fundamental Rating

2

Overall SOPH gets a fundamental rating of 2 out of 10. We evaluated SOPH against 36 industry peers in the Health Care Technology industry. Both the profitability and financial health of SOPH have multiple concerns. SOPH is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year SOPH has reported negative net income.
In the past year SOPH has reported a negative cash flow from operations.
In the past 5 years SOPH always reported negative net income.
In the past 5 years SOPH always reported negative operating cash flow.
SOPH Yearly Net Income VS EBIT VS OCF VS FCFSOPH Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 -20M -40M -60M -80M

1.2 Ratios

SOPH has a worse Return On Assets (-45.10%) than 77.78% of its industry peers.
The Return On Equity of SOPH (-77.29%) is worse than 66.67% of its industry peers.
Industry RankSector Rank
ROA -45.1%
ROE -77.29%
ROIC N/A
ROA(3y)-38.14%
ROA(5y)-33.44%
ROE(3y)-53.54%
ROE(5y)-45.3%
ROIC(3y)N/A
ROIC(5y)N/A
SOPH Yearly ROA, ROE, ROICSOPH Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 -50 -100 -150

1.3 Margins

Looking at the Gross Margin, with a value of 68.09%, SOPH is in the better half of the industry, outperforming 72.22% of the companies in the same industry.
SOPH's Gross Margin has been stable in the last couple of years.
SOPH does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 68.09%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y2.64%
GM growth 5Y-0.84%
SOPH Yearly Profit, Operating, Gross MarginsSOPH Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024 0 50 -50 -100 -150

More info and screens

3

2. Health

2.1 Basic Checks

SOPH does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, SOPH has more shares outstanding
The number of shares outstanding for SOPH has been increased compared to 5 years ago.
Compared to 1 year ago, SOPH has a worse debt to assets ratio.
SOPH Yearly Shares OutstandingSOPH Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 2024 20M 40M 60M
SOPH Yearly Total Debt VS Total AssetsSOPH Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 2024 100M 200M 300M

2.2 Solvency

SOPH has an Altman-Z score of -1.91. This is a bad value and indicates that SOPH is not financially healthy and even has some risk of bankruptcy.
SOPH has a Altman-Z score of -1.91. This is in the lower half of the industry: SOPH underperforms 66.67% of its industry peers.
SOPH has a Debt/Equity ratio of 0.33. This is a healthy value indicating a solid balance between debt and equity.
SOPH has a worse Debt to Equity ratio (0.33) than 61.11% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.33
Debt/FCF N/A
Altman-Z -1.91
ROIC/WACCN/A
WACC4.97%
SOPH Yearly LT Debt VS Equity VS FCFSOPH Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 2024 0 100M 200M

2.3 Liquidity

A Current Ratio of 3.11 indicates that SOPH has no problem at all paying its short term obligations.
SOPH has a better Current ratio (3.11) than 72.22% of its industry peers.
A Quick Ratio of 2.94 indicates that SOPH has no problem at all paying its short term obligations.
SOPH has a Quick ratio of 2.94. This is in the better half of the industry: SOPH outperforms 72.22% of its industry peers.
Industry RankSector Rank
Current Ratio 3.11
Quick Ratio 2.94
SOPH Yearly Current Assets VS Current LiabilitesSOPH Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M 250M

More info and screens

6

3. Growth

3.1 Past

The Earnings Per Share has grown by an nice 10.71% over the past year.
Looking at the last year, SOPH shows a small growth in Revenue. The Revenue has grown by 4.66% in the last year.
Measured over the past years, SOPH shows a very strong growth in Revenue. The Revenue has been growing by 20.78% on average per year.
EPS 1Y (TTM)10.71%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-23.81%
Revenue 1Y (TTM)4.66%
Revenue growth 3Y17.23%
Revenue growth 5Y20.78%
Sales Q2Q%12.68%

3.2 Future

SOPH is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 13.25% yearly.
The Revenue is expected to grow by 25.25% on average over the next years. This is a very strong growth
EPS Next Y1.22%
EPS Next 2Y11.13%
EPS Next 3Y13.25%
EPS Next 5YN/A
Revenue Next Year13.88%
Revenue Next 2Y18.74%
Revenue Next 3Y21.11%
Revenue Next 5Y25.25%

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
SOPH Yearly Revenue VS EstimatesSOPH Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 50M 100M 150M 200M
SOPH Yearly EPS VS EstimatesSOPH Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 -0.5 -1 -1.5

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

SOPH reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for SOPH. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
SOPH Price Earnings VS Forward Price EarningsSOPH Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
SOPH Per share dataSOPH EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 1

4.3 Compensation for Growth

SOPH's earnings are expected to grow with 13.25% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y11.13%
EPS Next 3Y13.25%

More info and screens

0

5. Dividend

5.1 Amount

SOPH does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

SOPHIA GENETICS SA

NASDAQ:SOPH (7/11/2025, 8:00:02 PM)

3.49

-0.26 (-6.93%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Technology
Earnings (Last)05-06 2025-05-06/bmo
Earnings (Next)08-04 2025-08-04/bmo
Inst Owners48.28%
Inst Owner Change0%
Ins Owners6.53%
Ins Owner ChangeN/A
Market Cap233.24M
Analysts85.45
Price Target6.94 (98.85%)
Short Float %0.03%
Short Ratio0.23
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-1.83%
Min EPS beat(2)-2.99%
Max EPS beat(2)-0.67%
EPS beat(4)1
Avg EPS beat(4)-0.71%
Min EPS beat(4)-19.35%
Max EPS beat(4)20.18%
EPS beat(8)3
Avg EPS beat(8)2.28%
EPS beat(12)7
Avg EPS beat(12)8.94%
EPS beat(16)10
Avg EPS beat(16)10.55%
Revenue beat(2)1
Avg Revenue beat(2)0.55%
Min Revenue beat(2)-1.89%
Max Revenue beat(2)2.98%
Revenue beat(4)1
Avg Revenue beat(4)-2.94%
Min Revenue beat(4)-10.93%
Max Revenue beat(4)2.98%
Revenue beat(8)2
Avg Revenue beat(8)-2.64%
Revenue beat(12)3
Avg Revenue beat(12)-2.12%
Revenue beat(16)5
Avg Revenue beat(16)-0.8%
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-6.98%
EPS NY rev (1m)-2.6%
EPS NY rev (3m)-6.05%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0.17%
Revenue NY rev (1m)0.23%
Revenue NY rev (3m)1.13%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 3.47
P/FCF N/A
P/OCF N/A
P/B 2.72
P/tB 4.19
EV/EBITDA N/A
EPS(TTM)-1
EYN/A
EPS(NY)-0.73
Fwd EYN/A
FCF(TTM)-0.71
FCFYN/A
OCF(TTM)-0.59
OCFYN/A
SpS1.01
BVpS1.28
TBVpS0.83
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -45.1%
ROE -77.29%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 68.09%
FCFM N/A
ROA(3y)-38.14%
ROA(5y)-33.44%
ROE(3y)-53.54%
ROE(5y)-45.3%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y2.64%
GM growth 5Y-0.84%
F-Score3
Asset Turnover0.46
Health
Industry RankSector Rank
Debt/Equity 0.33
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 87.27%
Cap/Sales 11.48%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 3.11
Quick Ratio 2.94
Altman-Z -1.91
F-Score3
WACC4.97%
ROIC/WACCN/A
Cap/Depr(3y)130.72%
Cap/Depr(5y)142.16%
Cap/Sales(3y)16.39%
Cap/Sales(5y)15.38%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)10.71%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-23.81%
EPS Next Y1.22%
EPS Next 2Y11.13%
EPS Next 3Y13.25%
EPS Next 5YN/A
Revenue 1Y (TTM)4.66%
Revenue growth 3Y17.23%
Revenue growth 5Y20.78%
Sales Q2Q%12.68%
Revenue Next Year13.88%
Revenue Next 2Y18.74%
Revenue Next 3Y21.11%
Revenue Next 5Y25.25%
EBIT growth 1Y14.06%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year42.87%
EBIT Next 3Y21.93%
EBIT Next 5Y21.9%
FCF growth 1Y38.77%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y41.12%
OCF growth 3YN/A
OCF growth 5YN/A